Appointment
© Selvita SA

Selvita appoints new Chief Medical Officer

Selvita S.A., a clinical stage drug discovery and development company focused on innovative medicines for oncology patients and drug discovery services, announced today the appointment of Steffen Heeger, M.D., PhD, to the role of Chief Medical Officer.

Dr. Heeger will join Selvita in February and will be responsible for all clinical, medical affairs and regulatory functions for Selvita oncology pipeline including SEL24, the first-in-class dual PIM/FLT3 kinase inhibitor currently in Phase I/II studies in acute myeloid leukemia, SEL120, the first-in-class selective CDK8 kinase inhibitor, targeting hematological malignancies and solid tumors, currently in IND-enabling studies as well as new programs emerging from three Selvita’s discovery platforms – targeted therapeutics, cancer metabolism and immunometabolism, and immune-oncology.

Dr. Steffen Heeger is an oncologist with a thorough experience in oncology drug development. Prior to joining Selvita, Dr. Heeger held a position of Vice President, Head of Clinical Development and Head of Clinical Operations at Morphosys AG, where he focused on the development and execution of clinical strategy for Morphosys’ lead hematology and oncology products.